Theravance Bioph Stock Price, News & Analysis

Theravance Biopharma (NASDAQ: TBPH) will participate in two upcoming investor conferences: the Morgan Stanley 20th Annual Global Healthcare Conference on September 13 at 11:10 am ET and the H.C. Wainwright 24th Annual Global Investment Conference on September 14 at 1:30 pm ET. Both events will be webcast, accessible via Theravance.com. The company focuses on delivering innovative medicines, including the FDA-approved YUPELRI® for COPD. Event replays will be available for 30 days.

Theravance Biopharma (TBPH) reported strong Q2 2022 results with record net sales of YUPELRI® (revefenacin) at $17.2M, up 17% year-over-year. The company is advancing Ampreloxetine towards NDA filing after discussions with the FDA, requiring one additional Phase 3 study. A significant deal involved selling TRELEGY ELLIPTA royalty interests to Royalty Pharma for an upfront cash of $1.1 billion, potentially exceeding $1.5 billion in total value. The company anticipates becoming cash flow positive by the end of 2022.

Theravance Biopharma (NASDAQ: TBPH) will report its Q2 2022 financial results and provide a business update on August 4, 2022, after market close. A conference call will follow at 5:00 pm ET. The call can be accessed via phone or streamed online through the company's website. A replay will be available for 30 days post-call. Theravance is focused on delivering innovative medicines, including its FDA-approved YUPELRI® for COPD management.

Theravance Biopharma (NASDAQ: TBPH) announced a tender offer to purchase all outstanding 3.25% Convertible Senior Notes due 2023, totaling $230 million in aggregate principal. Investors will receive $1,000 for each $1,000 of notes, plus accrued interest, if accepted. The offer expires on August 23, 2022. The company plans to fund the purchase with cash on hand. The offer is subject to certain conditions, and no minimum amount of notes is required to be tendered.

Theravance Biopharma announced an agreement to sell its 85% interest in GSK's TRELEGY ELLIPTA royalty rights to Royalty Pharma for over $1.5 billion in potential value, including approximately $1.1 billion upfront. The deal aims to enhance shareholder value by eliminating debt and returning capital. Additionally, Royalty Pharma will invest $40 million to advance ampreloxetine development for MSA. Following the transaction, Theravance expects to have $430 million in cash and aims for breakeven cash flow in the second half of 2022.

Theravance Biopharma (NASDAQ: TBPH) reported Q1 2022 revenue of $13.2 million, a $1.1 million decrease from Q1 2021, due to the end of Janssen collaboration revenue. YUPELRI® net sales were $15.3 million, up 19% year-over-year, while TRELEGY's net sales hit $454 million, a 33% increase. R&D expenses dropped to $23.3 million from $67.6 million, and SG&A expenses fell to $19.1 million from $30.6 million. The operating loss decreased to $38.5 million compared to $83.9 million in the same period last year. The company expects to achieve sustainable cash-flow positivity in the second half of 2022.

Theravance Biopharma (NASDAQ: TBPH) will announce its first quarter 2022 financial results on May 5, 2022, after market close. A conference call will follow at 5:00 pm ET, providing insights into the company's performance. Investors can join via phone or by visiting the company’s website. A replay will be accessible for 30 days post-call. Theravance specializes in respiratory medicines, including the FDA-approved YUPELRI for chronic obstructive pulmonary disease (COPD). The company also has economic interests related to certain programs with GSK.

Theravance Biopharma (NASDAQ: TBPH) will present at the 21^st Annual Needham Virtual Healthcare Conference on April 13, 2022, at 1:30 pm ET. A webcast of the presentation can be accessed on the company's website under the Investors section and will be available for 30 days post-event.

The company focuses on developing respiratory medicines, with its notable product being YUPELRI^® for COPD treatment. Additionally, it has economic interests related to programs involving Glaxo Group Limited.

Theravance Biopharma (NASDAQ: TBPH) recently announced results from Phase 3 Study 0170 examining ampreloxetine for symptomatic neurogenic orthostatic hypotension (nOH). While the primary endpoint was not statistically significant for the overall patient population, MSA patients showed a promising 72% reduction in treatment failure odds. The company is pursuing strategic partnerships and planning discussions with health authorities to expedite development. They aim to achieve sustainable cash-flow positivity by the second half of the year, focusing on respiratory therapeutics and shareholder value creation.